Latest Breaking News On - Prevent recurrent preterm birth - Page 1 : comparemela.com

The FDA recommended that Covis Pharma's premature birth drug, Makena, be taken off the market. The company has refused. Covis has continued to promote Makena, emphasizing a need by Black women, who are most at risk of preterm births.

Kent nishimura los angelesGudemanjj perinatolCovis pharmaPublic health institute in oaklandAmerican college of obstetriciansAdvisory committeeBrittany horseyKent nishimuraLos angeles timesMakena care connectionPublic health instituteAmerican collegeMeis trialHydroxyprogesterone caproatePrevent recurrent preterm birthSingleton gestations